MRUS - Merus BV
Merus BV Logo

MRUS - Merus BV

https://www.merus.nl
Recent News
Powered by Alpha Vantage
AI Tools
Key Metrics
Trend: Downtrend
Source: Snapshot

Merus NV, a clinical-stage immuno-oncology company, is dedicated to the discovery and development of bispecific antibody therapies in the Netherlands. The company is headquartered in Utrecht, the Netherlands.

52W High
$69.20
52W Low
$33.19
MA Status:
50D: Below 200D: Below
Beta (~1 neutral, <0.9 lower risk)
1.19
Valuation
As of 2025-06-30 (Overview)
Trailing P/E (<15 better)
N/A
Forward P/E (<15 better)
N/A
EV/EBITDA (<8 favorable)
-4.91
EV/Revenue (<3 favorable)
78.32
P/S (TTM) (<3 favorable)
90.76
P/B (<3 favorable)
6.06
Ownership
Institution‑heavy
Source: Overview
Insiders (1–5% typical)
2.29%
Institutions (25–75% balanced)
103.79%
Shares Outstanding
75,634,000
Float
65,608,000
Dividend Yield (2–6% sweet spot)
N/A
Ex‑Dividend Date
N/A
Income & Growth
Profitability: Weak
As of 2025-06-30 (Overview)
Revenue (TTM)
56,228,000
Gross Profit (TTM)
-52,820,000
EPS (TTM)
-5.58
Profit Margin (>10% good)
N/A
Operating Margin (TTM) (higher better)
-12.50%
ROE (TTM) (>15% strong)
-0.49%
EPS YoY (Quarterly) (>10% good)
N/A
Revenue YoY (Quarterly) (>8% good)
0.20
Momentum
Value
N/A
Previous
N/A
Trend
—
Signal Cross
No cross
As of
—